Information  X 
Enter a valid email address

EPIC/TIDM matching 'GLPG'

Date
Time Source
Company
Announcement
14 Jul 2019 6:01 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION
02 Jul 2019 6:00 am GNW Report Factsheet Galapagos NV (GLPG) GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR
20 Jun 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
17 Jun 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Transparency notification
11 Jun 2019 6:00 am GNW Report Factsheet Galapagos NV (GLPG) Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
29 May 2019 9:30 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
25 Apr 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos reports on historic first quarter 2019
23 Apr 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
10 Apr 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos creates new warrant plans
29 Mar 2019 9:15 pm GNW Report Factsheet Galapagos NV (GLPG) Publication of the annual report and invitation to the annual shareholders' meeting
28 Mar 2019 9:22 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
  9:07 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
  9:01 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
  9:00 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
20 Mar 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
21 Feb 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Firmly on our way to becoming a fully integrated biopharma company
07 Feb 2019 6:30 am GNW Report Factsheet Galapagos NV (GLPG) Evotec and Galapagos enter into collaboration in the field of fibrosis
08 Jan 2019 9:02 pm GNW Report Factsheet Galapagos NV (GLPG) Sands Capital reports 5.7% holding in Galapagos
07 Jan 2019 6:30 am GNW Report Factsheet Galapagos NV (GLPG) Galapagos starts first Phase 1 trial with Toledo compound
06 Jan 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
04 Jan 2019 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Fibrocor and Galapagos sign partnership in fibrosis
21 Dec 2018 9:02 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
17 Dec 2018 9:19 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
27 Nov 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
26 Nov 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Transparency notification
23 Nov 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
31 Oct 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)
24 Oct 2018 9:03 pm GNW Report Factsheet Galapagos NV (GLPG) Hallmark third quarter 2018 and Annual R&D Update at Galapagos
  9:02 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos and AbbVie restructure CF collaboration
  9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Topline interim results of FALCON trial Part 1 in CF
22 Oct 2018 6:15 pm GNW Report Factsheet Galapagos NV (GLPG) POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET
20 Oct 2018 11:30 pm GNW Report Factsheet Galapagos NV (GLPG) PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING
03 Oct 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
24 Sep 2018 6:30 am GNW Report Factsheet Galapagos NV (GLPG) Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients
17 Sep 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos issues new shares as result of public offering
  9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million
13 Sep 2018 9:02 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
  2:15 am GNW Report Factsheet Galapagos NV (GLPG) Galapagos raises $300 million gross proceeds in a U.S. public offering
12 Sep 2018 9:53 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos announces launch of proposed public offering
  9:01 pm GNW Report Factsheet Galapagos NV (GLPG) MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
11 Sep 2018 9:05 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS
06 Sep 2018 6:00 am GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
02 Aug 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Productive first half-year at Galapagos
19 Jul 2018 6:15 am GNW Report Factsheet Galapagos NV (GLPG) MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
26 Jun 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
20 Jun 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
14 Jun 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Transparency notification
30 May 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS
20 May 2018 7:30 pm GNW Report Factsheet Galapagos NV (GLPG) GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
01 May 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
24 Apr 2018 7:45 am GNW Report Factsheet Galapagos NV (GLPG) Galapagos reports initiation of FALCON clinical trial in cystic fibrosis
19 Apr 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos creates new warrant plan
12 Apr 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos announces ISABELA Phase 3 program in IPF
23 Mar 2018 8:30 pm GNW Report Factsheet Galapagos NV (GLPG) Publication of the annual report and invitation to the annual shareholders' meeting
20 Mar 2018 9:02 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
22 Feb 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Galapagos delivered in 2017
17 Feb 2018 9:00 am GNW Report Factsheet Galapagos NV (GLPG) Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
07 Jan 2018 9:00 pm GNW Report Factsheet Galapagos NV (GLPG) Positive topline results with GLPG1972 in osteoarthritis patients
02 Jan 2018 9:01 pm GNW Report Factsheet Galapagos NV (GLPG) Update on progress in cystic fibrosis programs
18 Dec 2017 6:30 am GNW Report Factsheet Galapagos NV (GLPG) Transparency notification


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t